Compare Pfizer Inc (PFE) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Shell PLC — how do they compare? Pfizer Inc trades at $28.13 (market cap $158.56B), while Shell PLC trades at $100.97 (market cap $284.34B). The key difference: Shell PLC is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Shell PLC for 90 Days on average.
| PFE | SHEL | |
|---|---|---|
Market Cap | $158.56B | $284.34B |
Volume | 44,138,282 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $29.02 | $100.20 |
52-Week Low | $23.67 | $70.31 |
Typical Hold Time | 158 Days | 90 Days |
Enterprise Value | $210.06B | $326.04B |
Dividend Yield | 6.18% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Shell (SHEL) trades at $96.85, down 0.79% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company's valuation ratios are attractive, with a P/E of 11.08 and P/S of 0.97, while profitability metrics like a 14.35% ROE and 8.76% net margin reflect solid fundamentals. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, positioning Shell for long-term growth in energy transition markets.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, but risks involve volatile oil prices and execution challenges in new projects. The stock offers value with upside potential, though investors should monitor energy market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
